The Key Points Of The Guideline On Prostate Cancer Screening

Prostate cancer screeningCrucial for further improvement of early detection for prostate cancer is a safe diagnostic distinction between requiring treatment and not to be treated cases. In the article " The key points of the guideline for prostate cancer early diagnosis " of Prof. Dr. M. Wirth , Dresden you will find a comprehensive description of this new S3 guideline .

The key points of the guideline on prostate cancer screeningIn Germany currently has about 32,000 prostate cancers are diagnosed . So the prostate ( prostate ) with 18.7 percent now the most common site of malignant neoplasms in men and has replaced since 1998 the lung cancer as the most common tumor in men. In the cancers leading to death of prostate cancer is 10.5 per cent in third place. The median age at diagnosis is comparatively high 72 years , 6 years higher than for cancer overall. First diseases are hardly before the 50th Years on .

Since the end of the 80s be observed in Germany , a steep rise in the incidence rates , which is still continuing . This can be mostly attributed to the application of new methods for the diagnosis such as the determination of prostate specific antigen (PSA). Autopsy studies show a large percentage of undetected , asymptomatic prostate cancers in the 70 - , in particular more than 80 years for men who undiscovered had no effect on life expectancy and quality of life of those affected. Crucial for further improvement of early detection for prostate cancer is therefore safe diagnostic distinction between requiring treatment and not to be treated cases. Prostate cancer can also be cured only in the early stages.

For this reason, the Federal Association of prostate cancer self-help eV (BPS have the German Society of Urology ( DGU) , the Professional Association of German Urologists , the Association of Urological Oncology ( AUO) , the German Cancer Society ( DKG ) , the German Cancer Aid ( DKH ) , ) , the working Group on laboratory Diagnostics of the German Urologists and the Association of the Scientific Medical society ( AWMF ) - that all important professional societies in this area - developed in an interdisciplinary consensus a set of guidelines for PSA testing in prostate cancer diagnosis. It meets the criteria of the currently highest scientific standards and is named after two nominal group processes , including the evidence-based medicine a S-3 guideline.

Guidelines for the PSA test in prostate cancer diagnosis - Summary (early detection of prostate cancer )

- The age of entry into the annual early diagnosis is 50 years .- Age of familial is 45 years.- One last early detection is carried out with 75 years , life expectancy increases later.- The digital rectal palpation alone is not a screening test , it is complemented by the determination of PSA .- Before the PSA value determining the necessary education on the following expectant measures such as biopsy of the prostate, the treatment and its risks is necessary.- An elevated PSA level should be checked before further diagnostics. Sources of error in the pre- diagnostics and analytics must be observed and excluded.- The threshold of 4.0 ng / ml , we currently seen as an indication for further evaluation with a biopsy under sonographic control and antibiotic coverage .- Punch biopsies are therefore mainly carried out in the known common tumor regions laterally.- The number of biopsies is dependent on the determined by transrectal ultrasonography of the prostate volume , but at least 6 biopsies. A higher number improves the diagnosis of carcinoma .- If a non-unique or doubtful biopsy findings , lack of cancer detection at constant or rising PSA level , a High Grade PIN ( prostatic intraepithelial neoplasia) or ASAP ( atypical small acinar proliferation ), a Rebiopsie with at least six tissue samples within 6 months after made the completion of all intra-and extraprostatic confounders .

Through such an examination , the tumor may be discovered in the curable stage . The PSA value can be determined nationwide. The required blood test is unreasonable. The determination of PSA for early detection of prostate cancer is essential according to current knowledge . The population must necessarily be informed about this possibility of early detection